Literature DB >> 15653436

Pathophysiology and diagnostic value of urinary trypsin inhibitors.

Michael J Pugia1, John A Lott.   

Abstract

Inflammation is an important indicator of tissue injury. In the acute form, there is usually accumulation of fluids and plasma components in the affected tissues. Platelet activation and the appearance in blood of abnormally increased numbers of polymorphonucleocytes, lymphocytes, plasma cells and macrophages usually occur. Infectious disorders such as sepsis, meningitis, respiratory infection, urinary tract infection, viral infection, and bacterial infection usually induce an inflammatory response. Chronic inflammation is often associated with diabetes mellitus, acute myocardial infarction, coronary artery disease, kidney diseases, and certain auto-immune disorders, such as rheumatoid arthritis, organ failures and other disorders with an inflammatory component or etiology. The disorder may occur before inflammation is apparent. Markers of inflammation such as C-reactive protein (CRP) and urinary trypsin inhibitors have changed our appraisal of acute events such as myocardial infarction; the infarct may be a response to acute infection and (or) inflammation. We describe here the pathophysiology of an anti-inflammatory agent termed urinary trypsin inhibitor (uTi). It is an important anti-inflammatory substance that is present in urine, blood and all organs. We also describe the anti-inflammatory agent bikunin, a selective inhibitor of serine proteases. The latter are important in modulating inflammatory events and even shutting them down.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15653436     DOI: 10.1515/CCLM.2005.001

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  23 in total

1.  Immunological evaluation of urinary trypsin inhibitors in blood and urine: role of N- & O-linked glycoproteins.

Authors:  Michael J Pugia; Saeed A Jortani; Manju Basu; Ronald Sommer; Hai-Hang Kuo; Solomon Murphy; Doug Williamson; James Vranish; Patrick J Boyle; Danny Budzinski; Roland Valdes; Subhash C Basu
Journal:  Glycoconj J       Date:  2007-01       Impact factor: 2.916

2.  Elevated plasma cryofibrinogen in patients with active inflammatory bowel disease is morbigenous.

Authors:  Koji Sawada; Ryouki Takahashi; Abbi R Saniabadi; Maiko Ohdo; Takashi Shimoyama
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

3.  Sulfation of the bikunin chondroitin sulfate chain determines heavy chain·hyaluronan complex formation.

Authors:  Megan S Lord; Anthony J Day; Peter Youssef; Lisheng Zhuo; Hideto Watanabe; Bruce Caterson; John M Whitelock
Journal:  J Biol Chem       Date:  2013-06-25       Impact factor: 5.157

4.  Determination of urinary trypsin inhibitor provides insight into postoperative complications in patients following esophagectomy.

Authors:  Ichiro Akagi; Masao Miyashita; Ken Takahashi; Takeshi Matsutani; Akihisa Matsuda; Tsutomu Nomura; Hiroshi Makino; Nobutoshi Hagiwara; Eiji Uchida
Journal:  Exp Ther Med       Date:  2012-04-18       Impact factor: 2.447

5.  Urinary trypsin inhibitor: miraculous medicine in many surgical situations?

Authors:  Jong In Han
Journal:  Korean J Anesthesiol       Date:  2010-04-28

Review 6.  Ulinastatin for acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis.

Authors:  Yu-Xin Leng; Shu-Guang Yang; Ya-Han Song; Xi Zhu; Gai-Qi Yao
Journal:  World J Crit Care Med       Date:  2014-02-04

7.  Myocardial protective effect by ulinastatin via an anti-inflammatory response after regional ischemia/reperfusion injury in an in vivo rat heart model.

Authors:  Il-Woo Shin; In-Seok Jang; Seung-Min Lee; Kyeong-Eon Park; Seong-Ho Ok; Ju-Tae Sohn; Heon-Keun Lee; Young-Kyun Chung
Journal:  Korean J Anesthesiol       Date:  2011-12-20

8.  The anti-inflammatory effects of ulinastatin in trauma patients with hemorrhagic shock.

Authors:  Kyung Hye Park; Kang Hyun Lee; Hyun Kim; Sung Oh Hwang
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

9.  The effect of ulinastatin on hemostasis in major orthopedic surgery.

Authors:  Jin Young Lee; Ji Young Lee; Jin Young Chon; Ho Sik Moon; Sung Jin Hong
Journal:  Korean J Anesthesiol       Date:  2010-01-31

10.  Ulinastatin reduces cancer recurrence after resection of hepatic metastases from colon cancer by inhibiting MMP-9 activation via the antifibrinolytic pathway.

Authors:  Bo Xu; Kun-Ping Li; Fei Shen; Huan-Qing Xiao; Wen-Song Cai; Jiang-Lin Li; Qi-Cai Liu; Lin Jia
Journal:  Biomed Res Int       Date:  2013-04-23       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.